



IACH

Diagnostic Challenges in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Impact of Expert Pathology Review

W.Chaaouri¹, W.Miled¹, M.Sayadi¹, R.Mansouri¹, K.Kacem¹, R.Benlakhel¹

¹Aziza Othmana Hospital, clinical hematology department, Tunis, Tunisia

INTRODUCTION

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B-cell lymphoma with distinct clinicopathological features [1]. However, its histological overlap with other lymphoid malignancies makes diagnosis challenging and may lead to inappropriate management [2].

The objective of this study was to evaluate the diagnostic challenges of NLPHL and assess the impact of expert pathology review on diagnostic accuracy.

METHODS

We retrospectively analyzed patients diagnosed with NLPHL in the Hematology Department of Aziza Othmana Hospital over an 11-year period. Histopathological specimens underwent expert review at a reference center whenever available. Diagnosis was supported by an extended immunohistochemical panel including B-cell markers, B-cell transcription factors, and classical Hodgkin lymphoma markers.

RESULTS

- ✓ Fifteen patients were included.
- ✓ Median age: 34 years [5–60].
- ✓ All patients presented with peripheral lymphadenopathy.
- ✓ Histopathological review and immunohistochemical findings are summarized in Figure 1.




Figure1: Histopathological and immunohistochemical findings in NLPHL

CONCLUSION

Nearly half of the cases required diagnostic revision after expert pathology review, highlighting the high risk of misclassification. Expert hematopathology review combined with comprehensive immunohistochemistry is essential for accurate diagnosis and optimal management of NLPHL.

REFERENCES

1. Sidda A, Naleid NK, Manu G, Graffeo V, Jamil MO. Nodular lymphocyte-predominant Hodgkin lymphoma: review of current literature and case discussion. J Investig Med High Impact Case Rep. 2022;10:2324709622111767.
2. Borchmann P, Eichenauer DA, Frigola G, Campo E. Nodular lymphocyte-predominant Hodgkin lymphoma: update on biology and treatment. Hematol Oncol. 2025;43(Suppl 2).

CONTACT

Chaaouriwiem2@gmail.com

www.iachlive.cme-congresses.com